V Square Quantitative Management LLC Reduces Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

V Square Quantitative Management LLC cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,540 shares of the medical equipment provider’s stock after selling 120 shares during the quarter. V Square Quantitative Management LLC’s holdings in Zimmer Biomet were worth $585,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. CWM LLC increased its position in shares of Zimmer Biomet by 7.4% during the third quarter. CWM LLC now owns 6,966 shares of the medical equipment provider’s stock valued at $752,000 after buying an additional 481 shares during the period. Exchange Traded Concepts LLC increased its position in shares of Zimmer Biomet by 3,043.1% during the third quarter. Exchange Traded Concepts LLC now owns 1,603 shares of the medical equipment provider’s stock valued at $173,000 after buying an additional 1,552 shares during the period. NBC Securities Inc. bought a new stake in shares of Zimmer Biomet during the third quarter valued at about $105,000. Trust Co. of Vermont increased its position in shares of Zimmer Biomet by 29.5% during the third quarter. Trust Co. of Vermont now owns 2,487 shares of the medical equipment provider’s stock valued at $268,000 after buying an additional 566 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of Zimmer Biomet by 1.5% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 22,230 shares of the medical equipment provider’s stock valued at $2,400,000 after buying an additional 337 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ZBH shares. JMP Securities reiterated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays decreased their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Up 0.6 %

Shares of Zimmer Biomet stock opened at $100.52 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The stock has a market capitalization of $20.01 billion, a price-to-earnings ratio of 22.59, a P/E/G ratio of 1.83 and a beta of 1.02. The company’s 50 day moving average price is $106.34 and its 200-day moving average price is $107.72.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the business earned $2.20 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.96%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.